Sino Biopharmaceutical (OTCMKTS:SBMFF) Shares Gap Down - Time to Sell?

Key Points

• Sino Biopharmaceutical's shares gapped down from $1.07 to $0.99 at market open on Thursday, with current trading volume at 3,000 shares.
• The company's 50-day moving average is $1.05, while its 200-day moving average stands at $0.75, indicating a recent drop in stock performance.
• Sino Biopharmaceutical operates in the Chinese pharmaceutical sector, focusing on oncology, liver disease, and respiratory system medications.

Shares of Sino Biopharmaceutical (OTCMKTS:SBMFF - ) gapped down before the market opened on Thursday . The stock had previously closed at $1.07, but opened at $0.99. Sino Biopharmaceutical shares last traded at $0.99, with a volume of 3,000 shares.

Sino Biopharmaceutical Price Performance

The business's 50 day moving average is $1.05 and its 200 day moving average is $0.75.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.